• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肌肉减少症、嗜酸性粒细胞与血小板比值及C反应蛋白作为慢性阻塞性肺疾病急性加重患者不良事件的预测指标:一项前瞻性观察研究

Sarcopenia, Eosinophil-to-Platelet Ratio, and C-reactive Protein as Predictors of Adverse Events in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Prospective Observational Study.

作者信息

Gandhi Rohankumar, Kalsariya Vijay, Katara Roshan, Murugan Yogesh

机构信息

Community and Family Medicine, Guru Gobindsingh Government Hospital, Jamnagar, IND.

Pulmonary Medicine, Guru Gobindsingh Government Hospital, Jamnagar, IND.

出版信息

Cureus. 2024 Mar 21;16(3):e56651. doi: 10.7759/cureus.56651. eCollection 2024 Mar.

DOI:10.7759/cureus.56651
PMID:38646255
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11032177/
Abstract

BACKGROUND

Biomarkers such as sarcopenia, eosinopenia, and C-reactive protein (CRP) may predict adverse events in chronic obstructive pulmonary disease (COPD) exacerbations. We aimed to determine their prognostic utility and accuracy versus conventional measures.

METHODS

This was a prospective analysis of COPD patients hospitalized for acute exacerbations for more than one year. Patients with primary diagnoses other than COPD were excluded. A total of 200 participants were screened, and 50 experienced adverse events, including mortality, rehospitalization, prolonged stay, hypoxemia, or hypercapnia. Data on demographics, lung function, symptoms, nutrition, frailty, sarcopenia, the eosinophil-to-platelet ratio (EPR), and CRP were extracted. Differences between groups were analyzed using t-tests and regression modeling.

RESULTS

Elevated CRP and a low EPR were significant predictors of adverse events after adjustment, with CRP having an area under the curve (AUC) of 0.71 (0.64-0.80) and EPR having an AUC of 0.76 (0.61-0.79) for composite outcomes. According to the multivariate logistic regression analysis, sarcopenia (adjusted Or (aOR)-1.97 (1.87-4.44)), EPR (aOR-2.33 (1.02-5.32)), and CRP (aOR-2.09 (1.01-3.18)) remained significant.

CONCLUSION

The EPR and CRP levels are useful prognostic markers of in-hospital morbidity and mortality during COPD exacerbations. However, multidimensional assessments incorporating other treatable traits may further optimize risk prediction and reduce adverse outcomes.

摘要

背景

肌肉减少症、嗜酸性粒细胞减少症和C反应蛋白(CRP)等生物标志物可能预测慢性阻塞性肺疾病(COPD)急性加重期的不良事件。我们旨在确定它们相对于传统指标的预后效用和准确性。

方法

这是一项对因急性加重住院超过一年的COPD患者的前瞻性分析。排除患有COPD以外原发性疾病的患者。共筛选了200名参与者,其中50人经历了不良事件,包括死亡、再次住院、住院时间延长、低氧血症或高碳酸血症。提取了人口统计学、肺功能、症状、营养、虚弱、肌肉减少症、嗜酸性粒细胞与血小板比值(EPR)和CRP的数据。使用t检验和回归模型分析组间差异。

结果

调整后,CRP升高和EPR降低是不良事件的显著预测因素,复合结局中CRP的曲线下面积(AUC)为0.71(0.64 - 0.80),EPR的AUC为0.76(0.61 - 0.79)。根据多因素逻辑回归分析,肌肉减少症(调整后比值比(aOR)-1.97(1.87 - 4.44))、EPR(aOR - 2.33(1.02 - 5.32))和CRP(aOR - 2.09(1.01 - 3.18))仍然具有显著性。

结论

EPR和CRP水平是COPD急性加重期院内发病和死亡的有用预后标志物。然而,纳入其他可治疗特征的多维评估可能会进一步优化风险预测并减少不良结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e21/11032177/705b1bf86005/cureus-0016-00000056651-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e21/11032177/705b1bf86005/cureus-0016-00000056651-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e21/11032177/705b1bf86005/cureus-0016-00000056651-i01.jpg

相似文献

1
Sarcopenia, Eosinophil-to-Platelet Ratio, and C-reactive Protein as Predictors of Adverse Events in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Prospective Observational Study.肌肉减少症、嗜酸性粒细胞与血小板比值及C反应蛋白作为慢性阻塞性肺疾病急性加重患者不良事件的预测指标:一项前瞻性观察研究
Cureus. 2024 Mar 21;16(3):e56651. doi: 10.7759/cureus.56651. eCollection 2024 Mar.
2
The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia.炎症标志物在预测伴或不伴嗜酸性粒细胞增多的慢性阻塞性肺疾病(COPD)病例再入院率和死亡率方面的效用。
Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2469-78. doi: 10.2147/COPD.S90330. eCollection 2015.
3
Statins versus placebo for people with chronic obstructive pulmonary disease.他汀类药物与安慰剂用于慢性阻塞性肺疾病患者的比较。
Cochrane Database Syst Rev. 2019 Jul 31;7(7):CD011959. doi: 10.1002/14651858.CD011959.pub2.
4
Frailty is a predictive factor of readmission within 90 days of hospitalization for acute exacerbations of chronic obstructive pulmonary disease: a longitudinal study.衰弱是慢性阻塞性肺疾病急性加重住院 90 天内再入院的预测因素:一项纵向研究。
Ther Adv Respir Dis. 2017 Oct;11(10):383-392. doi: 10.1177/1753465817726314. Epub 2017 Aug 29.
5
Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.慢性阻塞性肺疾病的炎症生物标志物与加重。
JAMA. 2013 Jun 12;309(22):2353-61. doi: 10.1001/jama.2013.5732.
6
C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT.C 反应蛋白即时检测用于安全减少慢性阻塞性肺疾病急性加重期抗生素使用的研究:PACE RCT。
Health Technol Assess. 2020 Mar;24(15):1-108. doi: 10.3310/hta24150.
7
Multidimensional Frailty Instruments Can Predict Acute Exacerbations Within One Year in Patients with Stable Chronic Obstructive Pulmonary Disease: A Retrospective Longitudinal Study.多维衰弱工具可预测稳定期慢性阻塞性肺疾病患者一年内的急性加重:一项回顾性纵向研究。
Int J Chron Obstruct Pulmon Dis. 2024 Apr 4;19:859-871. doi: 10.2147/COPD.S448294. eCollection 2024.
8
Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease.硫酸镁治疗慢性阻塞性肺疾病急性加重。
Cochrane Database Syst Rev. 2022 May 26;5(5):CD013506. doi: 10.1002/14651858.CD013506.pub2.
9
Proton pump inhibitors for chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病的质子泵抑制剂
Cochrane Database Syst Rev. 2020 Aug 25;8(8):CD013113. doi: 10.1002/14651858.CD013113.pub2.
10
Application Value of Blood Heparin-Binding Protein in the Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease.血液肝素结合蛋白在慢性阻塞性肺疾病急性加重诊断中的应用价值。
Contrast Media Mol Imaging. 2021 Dec 22;2021:3800211. doi: 10.1155/2021/3800211. eCollection 2021.

引用本文的文献

1
Frailty in COPD: Clinical Impact, Diagnosis, Biomarkers, and Management Strategies.慢性阻塞性肺疾病中的衰弱:临床影响、诊断、生物标志物及管理策略
Int J Chron Obstruct Pulmon Dis. 2025 Jul 15;20:2445-2458. doi: 10.2147/COPD.S522862. eCollection 2025.
2
A Pilot Study on Proteomic Predictors of Mortality in Stable COPD.稳定期 COPD 患者病死率的蛋白质组学预测指标的初步研究
Cells. 2024 Aug 14;13(16):1351. doi: 10.3390/cells13161351.

本文引用的文献

1
A Low Eosinophil to Platelet Ratio as a Worse Prognostic Index for Emergency Department Attendance in Acute Exacerbation of COPD.低嗜酸性粒细胞与血小板比值可作为 COPD 急性加重急诊就诊患者预后不良的预测指标。
Int J Chron Obstruct Pulmon Dis. 2024 Jan 16;19:139-147. doi: 10.2147/COPD.S442715. eCollection 2024.
2
Prevalence of sarcopenia in patients with COPD through different musculature measurements: An updated meta-analysis and meta-regression.通过不同肌肉测量方法评估慢性阻塞性肺疾病患者肌肉减少症的患病率:一项更新的荟萃分析和元回归分析
Front Nutr. 2023 Feb 16;10:1137371. doi: 10.3389/fnut.2023.1137371. eCollection 2023.
3
Sarcopenia index as a predictor of clinical outcomes among older adult patients with acute exacerbation of chronic obstructive pulmonary disease: a cross-sectional study.
骨骼肌减少症指数作为老年慢性阻塞性肺疾病急性加重患者临床结局的预测指标:一项横断面研究。
BMC Geriatr. 2023 Feb 11;23(1):89. doi: 10.1186/s12877-023-03784-7.
4
Comparison of CRP, Procalcitonin, Neutrophil Counts, Eosinophil Counts, sTREM-1, and OPN between Pneumonic and Nonpneumonic Exacerbations in COPD Patients.比较 COPD 患者肺部感染与非肺部感染加重期 CRP、降钙素原、中性粒细胞计数、嗜酸性粒细胞计数、sTREM-1 和 OPN 的差异。
Can Respir J. 2022 Mar 31;2022:7609083. doi: 10.1155/2022/7609083. eCollection 2022.
5
Incorporating Biomarkers in COPD Management: The Research Keeps Going.将生物标志物纳入慢性阻塞性肺疾病管理:研究仍在继续。
J Pers Med. 2022 Mar 1;12(3):379. doi: 10.3390/jpm12030379.
6
Blood Eosinophil and Risk of Exacerbation in Chronic Obstructive Pulmonary Disease Patients: A Retrospective Cohort Analysis.慢性阻塞性肺疾病患者血液嗜酸性粒细胞与急性加重风险:一项回顾性队列分析
Int J Chron Obstruct Pulmon Dis. 2020 Nov 10;15:2869-2877. doi: 10.2147/COPD.S268018. eCollection 2020.
7
Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis.诊断、患病率和 COPD 中肌肉减少症的临床影响:系统评价和荟萃分析。
J Cachexia Sarcopenia Muscle. 2020 Oct;11(5):1164-1176. doi: 10.1002/jcsm.12600. Epub 2020 Aug 30.
8
Sarcopenia: revised European consensus on definition and diagnosis.肌少症:定义和诊断的欧洲共识修订版。
Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.
9
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.COPD 加重的管理:欧洲呼吸学会/美国胸科学会指南。
Eur Respir J. 2017 Mar 15;49(3). doi: 10.1183/13993003.00791-2016. Print 2017 Mar.
10
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.全球慢性阻塞性肺疾病诊断、管理和预防策略 2017 年报告:GOLD 执行摘要。
Eur Respir J. 2017 Mar 6;49(3). doi: 10.1183/13993003.00214-2017. Print 2017 Mar.